Journal: Microbiology Spectrum

Article Title: Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease

doi: 10.1128/spectrum.03432-25

Figure Lengend Snippet: Eravacycline pharmacokinetics/pharmacodynamics in the HFS-MAB. ( A ) Concentration-time profile of eravacycline with different doses administered once daily. ( B ) Residuals from the pharmacokinetic modeling of the HFS-MAB measured eravacycline concentrations showing a good model fit. ( C ) Linear regression between the HFS-MAB measured eravacycline concentrations and model-predicted concentrations.

Article Snippet: Eravacycline minimum inhibitory concentration (MIC) (ATCC#19977 strain and 59 clinical isolates) ranged between 0.0075 and 0.3 mg/L, and the MIC 50 and MIC 90 were 0.15 and 0.3 mg/L, respectively.

Techniques: Drug discovery, Concentration Assay

Journal: Microbiology Spectrum

Article Title: Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease

doi: 10.1128/spectrum.03432-25

Figure Lengend Snippet: Eravacycline pharmacokinetics/pharmacodynamics in HFS-MAB. ( A ) Eravacycline time-kill curves with fluctuating drug concentrations using a once-daily dosing schedule. Eravacycline MIC of the reference ATCC#19977 strain was 0.15 mg/L. The HFS-MAB unit with AUC 0-24 /MIC of 145.47 showed contamination on study day 14; therefore, no data for this system were available for the later time points. ( B ) The inhibitory sigmoid maximal effect model fits for each sampling day to determine the relationship between eravacycline exposures and MAB bacterial burden.

Article Snippet: Eravacycline minimum inhibitory concentration (MIC) (ATCC#19977 strain and 59 clinical isolates) ranged between 0.0075 and 0.3 mg/L, and the MIC 50 and MIC 90 were 0.15 and 0.3 mg/L, respectively.

Techniques: Drug discovery, Sampling

Journal: Microbiology Spectrum

Article Title: Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium abscessus lung disease

doi: 10.1128/spectrum.03432-25

Figure Lengend Snippet: Dose-finding MCEs. ( A ) Concentration-time profiles in a 10,000 virtual patient simulation with eravacycline 1 mg/day dose in the serum and epithelial lining fluid (ELF). ( B ) Concentration-time profiles in a 10,000 virtual patient simulation with eravacycline 1 mg/day twice daily in the serum and ELF. ( C and D ) Probability of target attainment (AUC 0-24 /MIC of 3,588) in the lungs of patients with different eravacycline doses and once and twice-daily dosing schedules, considering the MIC distribution for 60 MAB isolates. ( E ) Cumulative fraction of response with eravacycline doses ranging from 0.5 to 4 mg/kg once or twice daily. Note, 4 mg/kg/day once daily will become a cumulative 8 mg/kg/day with a twice daily dosing schedule.

Article Snippet: Eravacycline minimum inhibitory concentration (MIC) (ATCC#19977 strain and 59 clinical isolates) ranged between 0.0075 and 0.3 mg/L, and the MIC 50 and MIC 90 were 0.15 and 0.3 mg/L, respectively.

Techniques: Concentration Assay